Page 7,073«..1020..7,0727,0737,0747,075..7,0807,090..»

Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM)

Posted: Published on February 29th, 2012

SUNRISE, Fla., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stem cell technology or LipiCell(TM) at the University of Miami Miller School of Medicine. Bioheart recently applied to the FDA to begin trials using adipose derived stem cells in patients with chronic ischemic cardiomyopathy. "Dr. Joshua Hare and the University of Miami are world leaders in the field of stem cell research," said Mike Tomas, President and CEO of Bioheart. "We look forward to working with these acclaimed experts and bringing the LipiCell(TM) technology to patients in the U.S." The clinical protocol of the ANGEL trial is designed to assess the safety and cardiovascular effects of intramyocardial implantation of autologous adipose derived stem cells (LipiCell(TM)) in patients with chronic ischemic cardiomyopathy. Joshua Hare, MD, Director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine is the principle investigator of the clinical program. The Interdisciplinary Stem Cell Institute was established to capitalize on pioneering work in the use of adult stem cells for the repair of malfunctioning human organs. The goal of the Institute is to find new treatments for heart … Continue reading →

Posted in Cell Medicine | Comments Off on Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM)

Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent …

Posted: Published on February 29th, 2012

CENTENNIAL, Colo.--(BUSINESS WIRE)-- Cell>Point today announced that it had entered into a licensing agreement for the countries of South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co., Ltd., headquartered in Seoul, South Korea. The license agreement covers the kit manufacture, marketing and distribution of Cell>Points cancer and cardiology imaging product based on its EthylenediCysteine-n-acetyl-Glucosamine (EC-G) technology platform. Specifically, the product is technetium-99m-labeled EC-G (99mTc-EC-G). In addition, HYUN IMC will be responsible for sponsoring clinical studies and seeking regulatory approval in each of the countries covered by the license. Cell>Point will receive an upfront payment, and development and regulatory milestone payments, as well as royalties on gross sales from HYUN IMC. We are confident that HYUN IMC will be an excellent partner that will affiliate with one of the leading Korean pharmaceutical companies to assist in the marketing of 99mTc-EC-G, said Greg Colip, Cell>Point CEO. The five Asia Pacific countries comprise approximately 296 million people, according to the CIA World Factbook. The company has already completed a Brazil license for the product, reaching Brazils 206 million citizens and the second fastest-growing market globally, behind only China, according to healthcare industry information provider IMS Health. 99mTc-EC-G, invented at The … Continue reading →

Posted in Cell Medicine | Comments Off on Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent …

Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent …

Posted: Published on February 29th, 2012

CENTENNIAL, Colo.--(BUSINESS WIRE)-- Cell>Point today announced that it had entered into a licensing agreement for the countries of South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co., Ltd., headquartered in Seoul, South Korea. The license agreement covers the kit manufacture, marketing and distribution of Cell>Points cancer and cardiology imaging product based on its EthylenediCysteine-n-acetyl-Glucosamine (EC-G) technology platform. Specifically, the product is technetium-99m-labeled EC-G (99mTc-EC-G). In addition, HYUN IMC will be responsible for sponsoring clinical studies and seeking regulatory approval in each of the countries covered by the license. Cell>Point will receive an upfront payment, and development and regulatory milestone payments, as well as royalties on gross sales from HYUN IMC. We are confident that HYUN IMC will be an excellent partner that will affiliate with one of the leading Korean pharmaceutical companies to assist in the marketing of 99mTc-EC-G, said Greg Colip, Cell>Point CEO. The five Asia Pacific countries comprise approximately 296 million people, according to the CIA World Factbook. The company has already completed a Brazil license for the product, reaching Brazils 206 million citizens and the second fastest-growing market globally, behind only China, according to healthcare industry information provider IMS Health. 99mTc-EC-G, invented at The … Continue reading →

Posted in Cell Medicine | Comments Off on Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent …

Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical …

Posted: Published on February 29th, 2012

SAN DIEGO, CA and PORTLAND, OR--(Marketwire -02/28/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today its Annual "Evening with Medistem" Event will take place in Portland, Oregon on March 7th, 2012. The event is being hosted by Vladimir Zaharchook, Vice Chairman at Medistem, Inc., and will feature stem cell luminaries and pioneers working with Medistem including Dr. Amit Patel, Director of Regenerative Medicine at University of Utah and the first person to administer stem cells into patients with heart failure, Dr. Michael Murphy, Vascular Surgeon at Indiana University and Principal Investigator for Medistem's FDA clinical trial in patients with risk of amputation, and Dr. Alan Lewis, former CEO of the Juvenile Diabetes Research Foundation, advisory board member of Medistem. In 2007 Medistem discovered an entirely new type of stem cell, the Endometrial Regenerative Cell (ERC). This cell has proven it is a "universal donor" and can be used to treat many more conditions compared to other types of stem cells. The company received FDA clearance to begin clinical trials in September of 2011 for critical limb ischemia, a condition that is associated with amputation. Medistem is also running a Phase II clinical trial for heart failure using the new stem … Continue reading →

Posted in Cell Medicine | Comments Off on Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical …

Stem Cell Therapy Procedure and Outcome – Video

Posted: Published on February 29th, 2012

28-02-2012 14:48 Albert Rodriguez, MD administers stem cell therapy for Hereditary Spastic Paraplegia. stemcelldrR.com, email airpainmd@aol.com See the original post: Stem Cell Therapy Procedure and Outcome - Video … Continue reading →

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Procedure and Outcome – Video

MWI to Market Innovative Canine Platelet Therapy from Pall Under SECUROS Brand

Posted: Published on February 29th, 2012

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced it has entered into an exclusive U.S. distribution agreement with leading animal health products provider MWI Veterinary Supply Co. As part of the agreement, MWI, through its SECUROS division, will market an innovative canine platelet enhancement therapy (C-PET) kit developed by Pall to treat dogs suffering from osteoarthritis as well as tendon and ligament injuries. The disposable system provides veterinarians a quick, portable and cost-effective solution for helping dogs realize long-term relief from these painful conditions. Osteoarthritis, a major concern for owners of the more than 72 million pet dogs1 in the United States, is a chronic condition characterized by pain and stiffness in the joints. Approximately one in five adult dogs in the U.S.2 suffer from osteoarthritis. Common canine treatment methods can range from weight control and exercise to the administration of nutraceuticals and anti-inflammatory drugs. In an effort to treat the condition rather than just the symptoms, many veterinarians have begun offering alternatives like minimally-invasive cell therapy procedures. Typically offered in conjunction with some of the more traditional methods, cell therapy can help accelerate healing and lead to longer-term relief. … Continue reading →

Posted in Cell Therapy | Comments Off on MWI to Market Innovative Canine Platelet Therapy from Pall Under SECUROS Brand

Sleeping Pills Linked to Death Risk: Which Prescriptions Are Dangerous, and Why?

Posted: Published on February 29th, 2012

According to new data from the Scripps Clinic Sleep Center in San Diego, people taking medication for insomnia now have something else to lose sleep over. Research published yesterday in the medical journal BMJ by Daniel F. Kripke, Robert D. Langer and Lawrence E. Kline points to very strong links between sleeping pills and early death. This was a large study with clear, compelling and statistically significant findings. "The results were pretty surprising," said Kripke in an interview with Time. "And as far as I know, the mortality and cancer risks are not reflected in any [sleep aid medication] labels." The study followed 10,529 people who took sleeping pills, as well as about 23,676 others who did not, for about 2.5 years between 2002 and 2007. The subjects' average age was 54. Like us on Facebook Even those who took less than 18 pills a year faced increased mortality--they were 3.6 times more likely to die than non-users. Those who took between 18 and 132 doses a year were four times more likely, and those who took 132 or more were five times more likely. These are frightening statistics for the 6 to 10 percent of Americans who use sleeping … Continue reading →

Posted in Prescriptions | Comments Off on Sleeping Pills Linked to Death Risk: Which Prescriptions Are Dangerous, and Why?

Rottenstein Law Group Hopes for Big Benefits from Small Device

Posted: Published on February 29th, 2012

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is cautiously optimistic about a new medical device designed to eliminate the need for regular self-injection of medication. (PRWEB) February 28, 2012 Robert Langer and Michael Cima, two MIT researchers working with the company MicroCHIPS, Inc., have developed a microchip implant capable of delivering prescription medications to patients. The chip, in development for about ten years, just completed its first human test, prompting the researchers to claim, It passed with flying colors. The microchip implants were tested on seven women between the ages of 65 and 70 who suffer from osteoporosis. In all seven patients, the chip delivered the correct dose of medication without any adverse side effects. Some bisphosphonate medications are administered by injection, rather than in pill form like Fosamax. The idea behind the microchip implant is to effectively deliver an accurate dosing of medication while ensuring compliance on the part of patients. Many persons cannot, or will not inject themselves with medication. Cima commented in an MIT press release: Compliance is very important in a lot of drug regimens, and it can be very difficult to get patients … Continue reading →

Posted in Drug Side Effects | Comments Off on Rottenstein Law Group Hopes for Big Benefits from Small Device

Modified bone drug kills malaria parasite

Posted: Published on February 29th, 2012

Washington, Feb 28 (IANS) A modified osteoporosis drug may prove to be a boon in fighting malaria, which works at very low concentrations and has no side-effects. Osteoporosis is the thinning of bone tissue and loss of bone density over time, increasing the risk of fractures. Unlike similar compounds tested against other parasitic protozoa, the new drug BPH-703 readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite. University of Illinois at Urbana-Champaign researchers found the drug by screening a library of about 1,000 compounds used in targeting a key enzyme in an important biochemical pathway (isoprenoid biosynthesis) in cancer and in disease-causing organisms, the journal proceedings of the National Academy of Sciences reports. The new drug lead, BPH-703, inhibits a key enzyme in isoprenoid biosynthesis that enables the malaria parasite to defend itself from the host immune system. The drug has little effect on the same chemical pathway in human or mouse cells, said Illinois chemistry professor Eric Oldfield, who led the study, according to an Illinois statement. The lead compounds are chemically modified forms of the osteoporosis drugs Actonel (Risedronate) and Zometa (Zoledronate), Oldfield said. The World Health Organization estimates that malaria killed … Continue reading →

Posted in Drug Side Effects | Comments Off on Modified bone drug kills malaria parasite

FDA adds new safety information to statin drugs

Posted: Published on February 29th, 2012

WASHINGTON (AP) -- Federal health officials are adding new safety warnings about risks of memory loss and elevated blood sugar to statins, the most widely prescribed group of cholesterol-lowering medications. The Food and Drug Administration said Tuesday it is making labeling changes to medicines like Pfizer Inc.'s Lipitor, AstraZeneca's Crestor and Merck & Co. Inc.'s Zocor. The drugs are used by tens of millions of U.S. patients to help prevent heart-related problems associated with cholesterol. New labeling on all such drugs will warn of memory loss and confusion reported among certain patients taking statins. In general the problems were not serious and went away after patients stopped taking the drugs, according to the FDA. The updated labels will also mention elevated levels of blood sugar, associated with diabetes, that have been reported in some patients taking statins. A growing number of studies published over the last five years have found a link between statin use and type 2 diabetes. Last June, a report in the Journal of the American Medical Association analyzed five older randomized trials and concluded the increased risk was small but real for people taking higher doses of any statin. Cardiologists said Tuesday that the lifesaving benefits … Continue reading →

Posted in Drugs | Comments Off on FDA adds new safety information to statin drugs

Page 7,073«..1020..7,0727,0737,0747,075..7,0807,090..»